Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes

Next Previous
X
Search
Trial Profile

Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin suspension isophane
  • Indications Gestational diabetes; Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jun 2015 Primary endpoint of mean blood glucose has not been met, according to results published in the American Journal of Obstetrics and Gynecology. (Although the primary endpoint met clinically, statistical significant difference did not achieve (p=0.2937)).
    • 09 Jun 2015 Results published in the American Journal of Obstetrics and Gynecology.
    • 09 Jun 2015 Status changed from recruiting to completed according to results published in the American Journal of Obstetrics and Gynecology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top